Frequency of Covid-19 Infection and The Disease Profile in Patients Followed with Multiple Sclerosis
Öz
Objective: For a long time immunomodulatory / immunosuppressive drugs have been used to slow the progression of multiple sclerosis (MS). These treatments are known to suppress the immune system and create susceptibility to infections. In our study, it was aimed to review the severity and frequency of COVID-19 disease in MS patients who received immunomodulatory/immunosuppressive treatments during the current coronavirus disease 2019 (COVID-19) pandemic, and also to evaluate whether they were adversely affected in terms of psychological outcomes.
Material and Methods: Participants consisted of MS patients who acquired COVID-19 (group 1) aged 18-65, using disease-modifying treatments (DMT) with follow-up in a neurology outpatient the clinic and the other two control groups consisted of similar ages and genders.
One of the other two groups is MS patients who have not had COVID-19 (group 2), the other group consisted of patients who had COVID-19 and did not have MS (group 3). MS profile, coronavirus anxiety scale (CAS), and Beck depression inventory (BDI) scales between groups 1 and 2; COVID-19 profile between groups 1 and 3 compared.
Results: As a result of comparing the MS disease profile of the 1st and 2nd groups and in terms of the COVID-19 disease profile of the 1st and 3rd groups, there was no statistically
a significant difference in these paired comparison groups (p> 0.05).
Conclusions: It was concluded that DMT use does not increase the severity of COVID-19 and having COVID-19 does not cause any additional changes in the psychiatric status of MS patients, since no a statistically significant difference was observed in the 2 MS group and 2 COVID-19 group comparison.
Anahtar Kelimeler
multiple sclerosis, infection, COVID-19, disease modifying treatment
Kaynakça
- Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res. 2019 Jan;68(1):25-38.
- Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis. 2018 Jul 16;5(8):ofy174.
- Williamson EML, Berger JR. Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. Neurotherapeutics. 2017 Oct;14(4):961-973.
- Grebenciucova E, Pruitt A. Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies. Curr Neurol Neurosci Rep. 2017 Sep 22;17(11):88.
- Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: The Dutch experience. Mult Scler. 2020 Sep;26(10):1256-1260.
- Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, et al. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. J Chin Med Assoc. 2020 Sep;83(9):817-821.
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17(2):162-73.
- Thakolwiboon S, Zhao-Fleming H, Pan J, Scott JK, Shoji E, Sohn G, et al. Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of International and National Recommendations. Int J MS Care. 2020;22(4):151-157.
- CDC. COVID-19 symptom list. https://www.cdc.gov/coronavirus/2019-ncov/symptoms- testing/symptoms.html. Accessed at 12.10.2020
- Bsteh G, Bitschnau C, Hegen H, Auer M, Di Pauli F, Rommer P, et al. Multiple sclerosis and COVID-19: how many are at risk? Eur J Neurol. 2020 Sep 25:10.1111/ene.14555.